Another party has thrown its hat into the ring in the fight to stop the issue of an Indian patent covering Sovaldi (sofosbuvir), a hepatitis C drug.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sovaldi, Gilead, patent opposition, Sankalp Rehabilitation Trust, Delhi High Court